Condition: Non-Small Cell Lung Cancer · Sponsor: Henan Genuine Biotech Co., Ltd.
This is an open-label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GEN-725 in combination with Dositinib in participants with locally advanced or metastatic EGFR-mutant non-small cell lung cancer.
This description comes directly from the study's public registry record.
Jun Zhou · 010-88196456 · ohjerry@163.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, China | Recruiting |
| Hunan Cancer Hospital | Changsha, China | Not Yet Recruiting |
| Cancer Hospital Affiliated to Shandong First Medical University (Shandong Cancer Hospital, Shandong cancer prevention and treatment institute) | Jinan, China | Not Yet Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07362940